New hope for patients out of options: experimental combo targets stubborn blood cancer
NCT ID NCT04764942
Summary
This study is testing a new combination of drugs for people with multiple myeloma, a blood cancer, that has come back and stopped responding to standard treatments. The main goals are to find the safest dose of the new drug selinexor when combined with other cancer drugs, and to see how well this combination works to control the disease. It is for adults whose cancer has progressed despite having tried several prior therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.